# United States Securities and Exchange Commission

## Statement of Changes in Beneficial Ownership

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

### Reporting Person

**Name:** Bancel Stephane  
**Last:**  
**First:**  
**Middle:**  
**C/O Moderna, Inc.**  
**200 Technology Square**  
**Cambridge, MA 02139**

### Issuer

**Issuer Name:** Moderna, Inc.  
**Ticker or Trading Symbol:** MRNA

### Transactions

<table>
<thead>
<tr>
<th>Date of Earliest Transaction</th>
<th>Security</th>
<th>Direct (D)</th>
<th>Number of Securities Acquired or Disposed of</th>
<th>Price (D)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/18/2021</td>
<td>Common Stock</td>
<td>$407</td>
<td>9,000</td>
<td>6,152,868</td>
<td></td>
</tr>
<tr>
<td>08/18/2021</td>
<td>Common Stock</td>
<td>$385</td>
<td>10,000</td>
<td>7,274,880</td>
<td></td>
</tr>
<tr>
<td>08/19/2021</td>
<td>Common Stock</td>
<td>$385</td>
<td>10,000</td>
<td>7,274,880</td>
<td></td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)</th>
<th>Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>Nature of Securities Beneficially Owned Following Transaction(s) (Instr. 3 and 4)</th>
<th>Title of Derivative Security (Instr. 5)</th>
<th>Price of Derivative Security (Instr. 6)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020.
2. The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 31, 2021.
3. The reported disposition represents a bona fide charitable gift made by the reporting person.
4. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.
5. These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
6. These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

### Signature

/s/ Brian Sandstrom, as Attorney-in-Fact  
08/20/2021

**Signature of Reporting Person**  
**Date**